Understanding Temporal Arteritis

Temporal arteritis, also known as giant cell arteritis, is a condition characterized by inflammation of the large and medium-sized arteries, primarily affecting the temporal arteries in the head. It is a serious condition that can lead to vision loss if not treated promptly. The mainstay of treatment involves the use of systemic corticosteroids, which help reduce inflammation and prevent complications.

Understanding Temporal Arteritis

Temporal arteritis typically affects individuals over the age of 50 and presents with symptoms such as headaches, scalp tenderness, jaw claudication, and visual disturbances. The exact cause is unknown, but it involves an abnormal immune response leading to inflammation of the arterial wall.

The Role of Systemic Corticosteroids

Systemic corticosteroids are the first-line treatment for temporal arteritis. They are effective in rapidly reducing arterial inflammation, alleviating symptoms, and preventing irreversible complications such as blindness. The goal is to initiate high-dose corticosteroids immediately upon suspicion of the diagnosis, even before biopsy results are available.

Mechanism of Action

Corticosteroids suppress the immune response, decrease inflammatory cytokine production, and stabilize the vascular endothelium. This reduces arterial wall inflammation and prevents further damage.

Commonly Used Corticosteroids

• Prednisone
• Prednisolone
• Methylprednisolone

Treatment Protocols

The typical initial dose of corticosteroids is high, often 40-60 mg of prednisone daily. The dose is gradually tapered based on clinical response and laboratory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).

Monitoring for side effects is essential during therapy. Long-term corticosteroid use can lead to osteoporosis, hyperglycemia, hypertension, and increased infection risk. Therefore, adjunctive treatments like calcium, vitamin D, and bisphosphonates are often recommended.

Managing Side Effects and Complications

Regular follow-up is necessary to monitor for adverse effects. Tapering should be done cautiously to prevent relapse. In some cases, steroid-sparing agents such as methotrexate or tocilizumab may be used to reduce corticosteroid dependency.

Conclusion

Systemic corticosteroids remain the cornerstone of treatment for temporal arteritis. Early initiation and careful management of therapy are crucial for preventing severe complications and ensuring optimal patient outcomes. Ongoing research continues to explore additional therapies to improve safety and efficacy.